Iconic Therapeutics Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

Iconic Therapeutics General Information

Description

Developer of immunoconjugate proteins intended to translate scientific insight into breakthrough medicines for serious diseases. The company's proteins work with the body's immune system to address the root causes of inflammation and angiogenesis together and potentially alter the course of leading causes of blindness, enabling physicians to develop a new approach to retinal disease and cancer.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Corporate Office
  • 701 Gateway Boulevard
  • Suite 100
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Iconic Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 01-Jun-2022 00000 Completed Generating Revenue
9. Later Stage VC 22-Aug-2019 00000 Completed Generating Revenue
8. Debt - General 28-Jun-2019 0000 00000 Completed Generating Revenue
7. Later Stage VC (Series B) 15-Apr-2019 0000 000.00 000.00 Completed Generating Revenue
6. Later Stage VC (Series C1) 09-Aug-2016 000.00 000.00 00000 Completed Generating Revenue
5. Accelerator/Incubator 10-Jul-2015 000.00 Completed Generating Revenue
4. Later Stage VC (Series B1) 16-Apr-2014 000.00 000.00 000.00 Completed Generating Revenue
3. Later Stage VC (Series C) 14-Jan-2009 00.000 000.00 000.00 Completed Generating Revenue
2. Later Stage VC 30-Apr-2007 $3.94M $8.62M 000.00 Completed Startup
1. Early Stage VC (Series A) 29-Dec-2004 $4.68M $4.68M 000.00 Completed Startup
To view Iconic Therapeutics’s complete valuation and funding history, request access »

Iconic Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B Prime 00,000,000 00.000000 00.00 00 00 00 00 00.000
Series A Prime 00,000,000 00.000000 00.00 00 00 00 00 00.000
To view Iconic Therapeutics’s complete cap table history, request access »

Iconic Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunoconjugate proteins intended to translate scientific insight into breakthrough medicines for serious d
Drug Discovery
South San Francisco, CA
9 As of 2022
00000
000000&0 00000

000 00

adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna ali
0000 000000000
Durham, NC
00 As of 0000
000.00
0000 0000-00-00
00000000000 000.00

000000

uip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
Cambridge, MA
00 As of 0000
0000
00000 0000-00-00
000000&0 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Iconic Therapeutics Competitors (90)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
T3D Therapeutics Venture Capital-Backed Durham, NC 00 000.00 00000000000 000.00
Mitobridge Formerly VC-backed Cambridge, MA 00 0000 000000&0 0000
Cerecin Venture Capital-Backed Singapore, Singapore 00 00000 00000000000 00000
Atomwise Venture Capital-Backed San Francisco, CA 00 00000 00000000000 00000
Neurona Therapeutics Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
You’re viewing 5 of 90 competitors. Get the full list »

Iconic Therapeutics Patents

Iconic Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190388522-A1 Methods for treating disorders associated with angiogenesis and neovascularization Inactive 25-Jan-2017 00000000000
EP-3573641-A1 Methods for treating disorders associated with angiogenesis and neovascularization Inactive 25-Jan-2017 00000000000
EP-3573641-A4 Methods for treating disorders associated with angiogenesis and neovascularization Inactive 25-Jan-2017 00000000000 0
US-20190153119-A1 Compositions and methods for treating disorders associated with neovascularization Inactive 14-Apr-2016 000000000
EP-3442554-A1 Compositions and methods for treating disorders associated with neovascularization Inactive 14-Apr-2016 C07K16/46
To view Iconic Therapeutics’s complete patent history, request access »

Iconic Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
William Greene MD Chief Executive Officer
Gabriela Burian MD Chief Medical Officer
You’re viewing 2 of 5 executive team members. Get the full list »

Iconic Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Iconic Therapeutics Former Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Advanced Technology Development Center Venture Capital Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Diem Bioventures Venture Capital Minority 000 0000 000000 0
Elm Street Ventures Venture Capital Minority 000 0000 000000 0
Georgia Research Alliance Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 16 investors. Get the full list »

Iconic Therapeutics FAQs

  • When was Iconic Therapeutics founded?

    Iconic Therapeutics was founded in 2002.

  • Who is the founder of Iconic Therapeutics?

    Kirk Dornbush JD is the founder of Iconic Therapeutics.

  • Who is the CEO of Iconic Therapeutics?

    William Greene MD is the CEO of Iconic Therapeutics.

  • Where is Iconic Therapeutics headquartered?

    Iconic Therapeutics is headquartered in South San Francisco, CA.

  • What is the size of Iconic Therapeutics?

    Iconic Therapeutics has 9 total employees.

  • What industry is Iconic Therapeutics in?

    Iconic Therapeutics’s primary industry is Drug Discovery.

  • Is Iconic Therapeutics a private or public company?

    Iconic Therapeutics is a Private company.

  • What is Iconic Therapeutics’s current revenue?

    The current revenue for Iconic Therapeutics is 000000.

  • How much funding has Iconic Therapeutics raised over time?

    Iconic Therapeutics has raised $105M.

  • Who are Iconic Therapeutics’s investors?

    Advanced Technology Development Center, Cormorant Asset Management, Diem Bioventures, Elm Street Ventures, and Georgia Research Alliance are 5 of 16 investors who have invested in Iconic Therapeutics.

  • Who are Iconic Therapeutics’s competitors?

    T3D Therapeutics, Mitobridge, Cerecin, Atomwise, and Neurona Therapeutics are some of the 90 competitors of Iconic Therapeutics.

  • When was Iconic Therapeutics acquired?

    Iconic Therapeutics was acquired on 01-Jun-2022.

  • Who acquired Iconic Therapeutics?

    Iconic Therapeutics was acquired by Endpoint Health.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »